Cytokinetics (CYTK) announced the launch of EARTH-HCM, an online, open access, interactive public health education tool developed by Cytokinetics in collaboration with leading academic institutions, that leverages real-world, de-identified claims data to visualize and analyze population differences in patient characteristics, treatments, clinical outcomes, healthcare resource utilization and costs in hypertrophic cardiomyopathy in the U.S. EARTH-HCM is a user-friendly, interactive tool designed to bridge the gap in awareness and education about HCM by providing insights into the treatment landscape and disparities in care. The tool was engineered to serve an array of stakeholders, including patients and caregivers, clinicians, pharmacists, researchers, policy decision-makers, payors and patient advocacy groups.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Promising Potential of Cytokinetics’ Aficamten in Cardiac Treatment Drives Buy Recommendation
- Cytokinetics’ data supports aficamten’s potential, says H.C. Wainwright
- Cytokinetics announces presentations as ACC Scientific Session & Expo
- Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment
- Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley
Questions or Comments about the article? Write to editor@tipranks.com